NM_004364.5:c.693C>G

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_004364.5(CEBPA):​c.693C>G​(p.Pro231Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00161 in 1,147,688 control chromosomes in the GnomAD database, including 26 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. P231P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.0071 ( 14 hom., cov: 32)
Exomes 𝑓: 0.00079 ( 12 hom. )

Consequence

CEBPA
NM_004364.5 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: -1.59

Publications

2 publications found
Variant links:
Genes affected
CEBPA (HGNC:1833): (CCAAT enhancer binding protein alpha) This intronless gene encodes a transcription factor that contains a basic leucine zipper (bZIP) domain and recognizes the CCAAT motif in the promoters of target genes. The encoded protein functions in homodimers and also heterodimers with CCAAT/enhancer-binding proteins beta and gamma. Activity of this protein can modulate the expression of genes involved in cell cycle regulation as well as in body weight homeostasis. Mutation of this gene is associated with acute myeloid leukemia. The use of alternative in-frame non-AUG (GUG) and AUG start codons results in protein isoforms with different lengths. Differential translation initiation is mediated by an out-of-frame, upstream open reading frame which is located between the GUG and the first AUG start codons. [provided by RefSeq, Dec 2013]
CEBPA-DT (HGNC:25710): (CEBPA divergent transcript)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.7).
BP6
Variant 19-33301722-G-C is Benign according to our data. Variant chr19-33301722-G-C is described in ClinVar as Benign/Likely_benign. ClinVar VariationId is 415195.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-1.59 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00714 (1059/148298) while in subpopulation AFR AF = 0.0246 (1010/41102). AF 95% confidence interval is 0.0233. There are 14 homozygotes in GnomAd4. There are 502 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position passed quality control check.
BS2
High AC in GnomAd4 at 1059 AD gene.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_004364.5. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CEBPA
NM_004364.5
MANE Select
c.693C>Gp.Pro231Pro
synonymous
Exon 1 of 1NP_004355.2
CEBPA
NM_001287424.2
c.798C>Gp.Pro266Pro
synonymous
Exon 1 of 1NP_001274353.1
CEBPA
NM_001287435.2
c.651C>Gp.Pro217Pro
synonymous
Exon 1 of 1NP_001274364.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
CEBPA
ENST00000498907.3
TSL:6 MANE Select
c.693C>Gp.Pro231Pro
synonymous
Exon 1 of 1ENSP00000427514.1
ENSG00000267727
ENST00000587312.1
TSL:3
n.356+88G>C
intron
N/A
CEBPA-DT
ENST00000718467.1
n.-32G>C
upstream_gene
N/A

Frequencies

GnomAD3 genomes
AF:
0.00713
AC:
1056
AN:
148192
Hom.:
14
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0246
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00194
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00641
Gnomad NFE
AF:
0.000150
Gnomad OTH
AF:
0.00392
GnomAD2 exomes
AF:
0.00133
AC:
2
AN:
1506
AF XY:
0.00120
show subpopulations
Gnomad AFR exome
AF:
0.0357
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.0294
GnomAD4 exome
AF:
0.000786
AC:
786
AN:
999390
Hom.:
12
Cov.:
29
AF XY:
0.000758
AC XY:
358
AN XY:
472284
show subpopulations
African (AFR)
AF:
0.0302
AC:
603
AN:
19956
American (AMR)
AF:
0.00279
AC:
16
AN:
5728
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
10448
East Asian (EAS)
AF:
0.00
AC:
0
AN:
17860
South Asian (SAS)
AF:
0.000158
AC:
3
AN:
19014
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
16690
Middle Eastern (MID)
AF:
0.00222
AC:
6
AN:
2698
European-Non Finnish (NFE)
AF:
0.0000920
AC:
80
AN:
869528
Other (OTH)
AF:
0.00208
AC:
78
AN:
37468
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.566
Heterozygous variant carriers
0
32
64
96
128
160
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
28
56
84
112
140
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00714
AC:
1059
AN:
148298
Hom.:
14
Cov.:
32
AF XY:
0.00694
AC XY:
502
AN XY:
72304
show subpopulations
African (AFR)
AF:
0.0246
AC:
1010
AN:
41102
American (AMR)
AF:
0.00194
AC:
29
AN:
14956
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3406
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5092
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4804
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
9124
Middle Eastern (MID)
AF:
0.00690
AC:
2
AN:
290
European-Non Finnish (NFE)
AF:
0.000150
AC:
10
AN:
66554
Other (OTH)
AF:
0.00388
AC:
8
AN:
2062
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
56
111
167
222
278
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00437
Hom.:
0

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Feb 22, 2024
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

Dec 14, 2020
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

not specified Benign:1
Nov 15, 2018
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Inborn genetic diseases Benign:1
Oct 02, 2024
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

Acute myeloid leukemia Benign:1
Jan 31, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.70
CADD
Benign
4.1
DANN
Benign
0.64
PhyloP100
-1.6
Mutation Taster
=100/0
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs550308123; hg19: chr19-33792628; COSMIC: COSV105200113; API